Gemneo tools and services
help researchers find rare cells
important to medicine.
What We Do
Gemneo Bioscience is the result of a 5-year, multi-million research journey at Arizona State University’s Biodesign Institute to develop innovative molecular-based single-cell genomics technology that does not require cell sorting, which will greatly accelerate the speed and decrease the costs of analyzing the genomic heterogeneity of cancer and immune tissues, microbiomes, and beyond. Gemneo’s mission is to put technology to work quickly -- in the hands of academic and pharma industry researchers -- to advance the frontiers of precision medicine, reduce costs, and improve patient outcomes.
The research on DNA Origami Nanoprobes for single-cell multi-gene analysis and single-cell analysis of tumor heterogeneity was funded by NIH grants and is an excellent example of federally-funded research leading to advances in science and medicine. Gemneo’s platform technology can be used to profile cancer genomics and identify rare cells that influence disease progression that current technologies are not able to detect.
Gemneo seeks to commercialize pioneering technology for single-cell genomics developed at Arizona State University’s (ASU) Biodesign Institute.
Why It Matters
Single-cell genomic analysis is an imperative to better understand genomic heterogeneity of cell populations involved in disease, and to identify the “rare” cells that influence disease progression.
Current tools for single-cell genomics are expensive and low-throughput, making the detection and characterization of rare cells costly and time consuming, and for very rare cells, all but impossible.
Single-cell genomics is emerging as a critical technology for enabling new types of therapies and diagnostics, including immunotherapies and genomic companion diagnostics for cancer. The Gemneo technology can greatly advance the goals of personalized medicine, by accelerating the speed and reducing the costs of single-cell genomic analysis.